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Abstract 
The psychostimulant drug ± 3,4-methylenedioxymethamphetamine (MDMA) reportedly 
produces distinctive feelings of empathy and closeness with others. MDMA increases social 
behavior in animal models and has shown promise in psychiatric disorders such as autism 
spectrum disorder (ASD) and post-traumatic stress disorder (PTSD). How it produces these 
prosocial effects is not known. This behavioral and psychophysiological study examined the 
effects of MDMA, compared to the prototypical stimulant methamphetamine (MA), on two 
measures of social behavior in healthy young adults: i) responses to socially relevant, “affective” 
touch, and ii) visual attention to emotional faces. Men and women (N=36) attended four sessions 
in which they received MDMA (0.75 or 1.5mg/kg), MA (20mg), or a placebo in randomized 
order under double-blind conditions. Responses to experienced and observed affective touch 
(i.e., being touched or watching others being touched) were assessed using facial 
electromyography (EMG), a proxy of affective state. Responses to emotional faces were assessed 
using electrooculography (EOG) in a measure of attentional bias. Subjective ratings were also 
included. We hypothesized that MDMA, but not MA, would enhance ratings of pleasantness and 
psychophysiological responses to affective touch and increase attentional bias toward positive 
facial expressions. Consistent with this, we found that MDMA, but not MA, selectively 
enhanced ratings of pleasantness of experienced affective touch. Neither drug altered ratings of 
pleasantness of observed touch. On the EOG measure of attentional bias, MDMA, but not MA, 
increased attention toward happy faces. These results provide new evidence that MDMA can 
enhance the experience of positive social interactions; in this case pleasantness of physical touch 
and attentional bias toward positive facial expressions. The findings are consistent with evidence 
that the prosocial effects are unique to MDMA relative to another stimulant. Understanding the 
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behavioral and neurobiological processes underlying the distinctive social effects of MDMA is a 
key step to developing the drug for psychiatric disorders. 
 
Introduction 
The psychostimulant drug ± 3,4-methylenedioxymethamphetamine (MDMA) has been 
labeled an “empathogen-entactogen,” and reportedly increases feelings of empathy and 
interpersonal closeness (Peroutka et al, 1988; Siegel, 1986). Laboratory studies in both rodents 
and healthy human volunteers support these reports. In rats, MDMA produces a distinctive 
tactile behavior of ‘adjacent lying’ between pairs of animals, and increases affiliative behaviors 
in non-human primates and cephalopods (Edsinger and Dölen, 2018; Pitts et al, 2017; Ramos et 
al, 2015; Thompson et al, 2009). In humans the drug increases self-report ratings of sociability 
and friendliness (Bedi et al, 2010; Bedi et al, 2009; Harris et al, 2002), as well as feelings of 
“trust,” “openness,” and “closeness with others” (Schmid et al, 2014). Notably, the effects of 
MDMA are distinct from the effects of other pharmacologically related psychostimulant drugs 
(Bershad et al, 2016a). To understand the psychological processes, and ultimately the 
neurobiological processes, that produce these distinctive social effects of MDMA, we and others 
have investigated the influence of the drug on standardized behavioral tasks believed to model 
aspects of social behavior (for reviews see Bershad et al, 2016a; Kamilar-Britt and Bedi, 2015).  
In the present placebo-controlled study, we investigated the effects of MDMA and the 
prototypical stimulant methamphetamine (MA) on two dimensions of responses to social stimuli; 
visual attention to faces expressing emotion and on a novel measure of affective responses to 
social touch.   
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The sense of touch is central to social communication (Gallace and Spence, 2010).  
However, the sense of touch has received little attention in human psychopharmacology. Of 
particular interest to social communication is “affective” touch, a socially relevant form of touch 
that is experienced as hedonically pleasant. Affective touch is believed to be mediated by 
activation of C-tactile (CT) afferents, located on non-glabrous (hairy) skin, and it is distinct from 
the ability to detect touch, which is processed via Aβ fibers (Abraira and Ginty, 2013; Olausson 
et al, 2010). The CT afferents show an inverted U-shaped firing frequency, with the touch 
velocities between 1-10 cm/s (“CT-optimal”) eliciting greater firing frequency than either faster 
or slower velocities. Corresponding with this, self-reported ratings of touch pleasantness follow 
this same inverted U-shape, with CT-optimal velocities rated as more pleasant than either faster 
or slower velocities (Löken et al, 2009), and pleasantness ratings are positively correlated with 
CT-fiber firing frequency. Psychophysiological responses to touch, such as facial 
electromyography (EMG) in follow a similar trend, where non-optimal velocities elicit an 
increase in negative affect that is mitigated by putative CT-afferent activation during CT-optimal 
touch (Mayo et al, 2018; Ree et al, 2018), and CT-optimal touch may enhance positive facial 
muscle responses (Pawling et al, 2017). Thus, this CT-firing mediated affective touch influences 
both the self-reported hedonic experience as well as the implicit facial muscle activity indicative 
of positive affective response. 
The positive hedonic qualities of affective touch may be due, in part, to unique neural 
and molecular underpinnings. CT-preferred stimulation activates dorsal posterior insula and 
orbitofrontal cortex and is related to the pleasurableness of the experience (Björnsdotter and 
Olausson, 2011; Francis et al, 1999; McGlone et al, 2014; Olausson et al, 2002; Olausson et al, 
2010; Perini and Olausson, 2015). The pleasantness of CT-optimal touch has been proposed to 
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be related to increased levels of serotonin and oxytocin (Trotter et al, 2016; Uvnäs-Moberg, 
1998; Walker and McGlone, 2013; Walker and McGlone, 2017a), both of which are influenced 
by MDMA.  Interestingly, recreational MDMA users report that MDMA increases the 
pleasantness of social touch (Klein et al, 2009). 
In the task used in the present study, we included both CT-optimal (“slow”; 3cm/s) and 
non-optimal (“fast”; 30cm/s) stroking. In one task, we measured how people responded to the 
experience of receiving CT-optimal and non-optimal touch. In a second task, we assessed how 
participants responded to the mere observation of others being touched, both at CT-optimal 
(3cm/s) or non-optimal (fast, 30 cm/s; static, 0 cm/s) velocities.  Several previous studies have 
reported that vicarious ratings of moving touch show the same relationship to stroking velocity 
as directly felt touch (Björnsdotter et al, 2011; Morrison et al, 2011; Walker et al, 2017b). In 
both tasks, we hypothesized that MDMA, but not MA, would increase perceived pleasantness of 
touch at the CT-optimal velocity. 
One index of potential drug-induced changes in social function is the ability of the drug 
to alter attention to positive versus negative social cues. To examine this idea we assessed the 
effects of the drug on participants’ visual attention to images of faces with varying emotional 
expressions, from positive (happy) to negative (fearful, sad, angry). We measured attention by 
recording eye movements in a dot probe task while subjects were shown two faces, either neutral 
or emotional, on two sides of the screen. This task has been shown to be sensitive to drug effects 
(Murphy et al, 2008), and to psychiatric symptoms related to social function: individuals with 
social anxiety exhibit increased vigilance toward threatening faces (Frewen et al, 2008). 
Conversely, some pharmacological manipulations, such as the administration of intranasal 
oxytocin, have been reported to enhance attention bias toward happy faces (Domes et al, 2013). 
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The findings regarding the effects of intranasal oxytocin on attention bias have been mixed, 
however. Domes et al. reported increased attention bias to positive stimuli but no effects on 
negative stimuli, whereas Kim et al. (2014) reported reduced attention toward negative 
expressions with no effect on positive expressions. It has been been suggested that MDMA 
produces prosocial effects by altering oxytocinergic signaling (Thompson et al, 2007), and in 
line with the effects of oxytocin on attention bias, we hypothesized that if MDMA is modifying 
attention through an oxytocinergic mechanism, then MDMA, but not MA (Bershad et al, 2016a), 
would positively bias visual attention.  
Thus, this study was designed to extend our understanding of how MDMA produces pro-
social effects, and how these effects differ from those of a prototypic psychostimulant.  The 
study was conducted in a laboratory setting under placebo-controlled double-blind conditions 
with healthy adult volunteers.  
Methods 
 
Study Design 
This study used a 4-session, within-subjects, double-blind design in which young adults received  
Placebo, 0.75mg/kg MDMA, 1.5mg/kg MDMA, or 20mg methamphetamine (MA) in 
randomized order during four 4-hour laboratory sessions. Outcome measures included subjective 
ratings of mood states and touch stimuli, psychophysiological responses, and visual attention to 
emotional faces. 
Participants 
Healthy volunteers (N = 36) aged 18 to 40 years were recruited from the University of Chicago 
and surrounding area. We recruited participants who reported between 4 and 40 uses of MDMA 
in their lifetime. At a screening session, participants underwent a physical and psychiatric 
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screening, which included an in-person psychiatric interview and detailed drug use history 
questionnaire, and electrocardiogram. Exclusion criteria were current diagnoses of psychiatric 
disorders including major depression (DSM 2015; APA 2006), serious medical condition, history 
of cardiac or liver disease, current or past substance abuse, individuals regularly using any 
contraindicated medications, and individuals with a previous negative reaction to MDMA. 
Women who were pregnant, planning to become pregnant, or lactating were excluded. Inclusion 
criteria were: fluency in English, a minimum of a high school education, and BMI between 19 
and 30 kg/m2. 
Study Drugs 
MDMA in powdered form (0.75mg/kg or 1.5mg/kg) or MA (20mg) was placed in opaque size 
00 capsules with lactose (USP) filler. Placebo capsules contained only lactose. These doses have 
previously been safely administered to healthy human participants (Bershad et al, 2016b; Mayo 
et al, 2013; Wardle et al, 2014b).  
Session Procedures 
Orientation 
During a 1-hour orientation session, participants were provided with information about the study 
and gave informed consent. The study was approved by the University of Chicago Institutional 
Review Board. Participants were told the goal of the study was to examine the effects of drugs 
on mood, perceptions, and behavior. To minimize expectancy effects, they were informed that 
they could receive a stimulant drug such as MDMA or methamphetamine, a sedative drug such 
as valium, a cannabinoid such as marijuana, or placebo. 
Study Sessions 
Participants completed four 4.5-hour sessions from 9:00 am to 1:30 pm. The sessions were 
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separated by at least 2 days and were conducted in a comfortably furnished room in a research 
laboratory containing chairs, a desk, computer, a television, video player, and reading materials. 
During the sessions, the participants were allowed to watch movies, read, or relax when not 
completing study questionnaires or tasks. Subjects were asked to abstain from drugs and alcohol 
for 48 hours before each session, and compliance was verified at the start of each session with a 
urine drug (ToxCup, Branan Medical Corporation) and breathalyzer tests (AlcosensorIII, 
Intoximeters). Women were also tested for pregnancy before each session (AimStickPBD, hCG 
professional, Craig Medical Distribution). After these tests, participants completed baseline 
measures for their mood and cardiovascular state (see below for mood and cardiovascular 
measures). At 9:30 am, participants took a capsule containing MA (20mg), MDMA (0.75 or 
1.5mg/kg), or placebo. Participants then relaxed for 1 hour, and subjective and cardiovascular 
measures were collected again at 10:00 am and 10:30 am. At 10:45 am, psychophysiological 
sensors were placed to collect facial EMG and EOG data, and participants completed the 
attention bias task, the observed touch task, and experienced touch task in randomized order. At 
11:45 am, the psychophysiological sensors were removed and subjective and cardiovascular 
measures were re-assessed at 12:30 pm and 1:00 pm. Participants then completed an end of 
session questionnaire and left the laboratory. After completing all sessions participants were 
provided with information on which drug or placebo they ingested at each of their study sessions, 
and were permitted to ask any questions they had about the study during a conversation with the 
researchers. Participants also received monetary compensation for their time. 
Subjective Questionnaires 
Drug Effects Questionnaire (DEQ) 
The DEQ consists of 5 questions on a visual analog scale assessing subjective drug effects. 
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Subjects were asked to rate the extent they felt a drug effect, whether they liked or disliked the 
drug effect, if they felt high, and if given a choice, whether they would want more of the drug. 
Visual Analog Scales (VAS)  
VAS consisted of adjectives tapping constructs that have previously been validated as sensitive 
to MDMA effects (Bershad et al, 2016b; Kirkpatrick et al, 2014b), including such words as 
“Sociable,” “Confident,” “Lonely,” “Playful,” “Dizzy,” “Loving,” “Friendly,” and ‘Restless” 
(Supplementary Table 1). 
End of Session Questionnaire (ESQ) 
This is a short questionnaire addressing which drug the participants believed they received and 
how much they would like to take the drug again. 
Behavioral Tasks 
Experienced Touch Task 
In this task, touch was administered using a 5 cm wide goat hair brush applied to a 9cm 
section of the forearm. We used brush rather than hand touching (i.e. skin-to-skin contact) to 
control for variation in skin temperature (Ackerley et al, 2014).  We used a hand-held brush, as 
previous reports indicate no difference in ratings of tactile stimulation delivered manually versus 
a force-controlled robot (Triscoli et al, 2013). Participants were instructed to look straight ahead 
at a fixation cross presented on a computer screen throughout the brushing trials to avoid 
providing any visual cues regarding touch administration. The experimenter wore headphones to 
receive metronomic audio cues for consistency in brushing velocity. The task consisted of four 
blocks of 8 trials each (32 total trials). Each trial consisted of 6 seconds of touch stimulation 
followed by ratings. Each block contained 8 trials, 4 of each velocity: 3 cm/s (“slow”) and 30 
cm/s (“fast”). Velocity order within each block pseudorandomized but not repeated more than 3 
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times. Affective responses to the brushing were measured using facial EMG (described below) 
and self-report ratings of pleasantness. Ratings were conducted during intertrial intervals using a 
7-point Likert scale ranging from 1 (extremely unpleasant) to 7 (extremely pleasant). A 1-2 sec 
variable inter-trial interval (ITI) separated each rating, with the final rating followed by a 7- 9 sec 
variable ITI before the next trial began.  
 
Observed Touch Task 
In the Observed Touch task, participants viewed 6 sec videos depicting a left arm (dorsal and 
ventral forearm and upper arm), back, or palm resting on a white background, being stroked by a 
hand at a rate of 0 (static), 3 or 30 cm/s. The task consisted of two repetitions of blocks of 60 
trials. A trial consisted of viewing touch being delivered to a given location [ back, medial 
forearm, lateral forearm, upper arm or palm] at one of the three velocities [0 cm/s (“static”), 3 
cm/s (“slow”) or 30 cm/s (“fast”)]. Within a block, each location x velocity combination was 
presented four times in a pseudorandomized order (no more than 3 consecutive identical 
locations or velocities). Facial muscle activity during video presentation was assessed via facial 
EMG, as described below. A 7.5 - 8.5 sec ITI followed each video, during which time 
participants rated the pleasantness of the video, similar to the experienced touch task. For the 
analysis presented here we used only ratings of touch to the three surfaces of the arm to be 
consistent with the experienced touch task. Data for all locations are presented in Supplementary 
Table 2.  
 
Facial Electromyography (EMG) 
Emotional reactivity to touch tasks was determined through EMG of corrugator and zygomatic 
musculature. EMG measures of these facial muscles’ activity are indicative of affective 
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responses to emotional stimuli and can provide another measure of emotional reactivity beyond 
subjective reports alone (Dimberg et al, 2000; Lang et al, 1993). Highly positive stimuli increase 
activity in the zygomatic, or “smile” muscle, and relax the corrugator (“frown”) muscle. 
Negative stimuli activate the corrugator muscle. EMG was recorded from 4 mm Ag/AgCl 
electrodes precisely placed on the cheek and left brow. An 8-mm Ag/AgCl ground sensor was 
placed on the subject’s forehead. Signals were amplified, filtered through a 10- to 500-Hz band 
pass, digitized, re-filtered, rectified, and then integrated over 20 milliseconds using EMG100C 
amplifiers, an MP150 Data Acquisition System, and Acqknowledge software from Biopac 
Systems (Goleta). 
Attention Bias Task (ABT) 
The ABT was adapted from Garner et al. (2006) and presented using E-Prime 2.0 software. 
Participants were shown pairs of faces, one on each side of the screen. Each pair contained one 
neutral face and one emotional expression face using the same actor. The emotional expressions 
were collected from the standardized Karolinska set (Goeleven et al, 2008). Each face pair 
presentation consisted of a 1-second pre-picture fixation, then a 2-second picture presentation. 
To distract the participants from the purpose of the task, a probe (either a square or a circle) was 
presented following the 2-second display of the face pair, and the participants were asked to 
indicate whether the shape presented was a square by pressing one keyboard key or if it was a 
circle by pressing a different key. After a response, or 10 seconds elapsed, an inter-trial interval 
of 750 to 1250 milliseconds began, followed by another trial. EOG was used to quantify which 
face was initially fixated on in each trial and was collected with 4 mm Ag/AgCl electrodes 
attached 1.5 cm from the outer canthus of each eye. The application and data collection process 
was the same as the EMG application and collection detailed above. Trained, blinded scorers 
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discarded trials in which the gaze was not centrally fixed prior to the trial, initial fixation was 
<100 milliseconds after picture onset, or noise obscured eye movements. Data were excluded for 
sessions prior to which subjects had four hours or less sleep, given the effects of sleep 
deprivation on attention (Lim and Dinges, 2010).    
Cardiovascular Measures 
Heart rate and blood pressure were monitored with portable monitors (Omron 10 Plus, Omron 
Healthcare) 5 times during the session (-15, 30, 60, 180, and 240 minutes post-drug 
 administration). Mean arterial pressure was calculated using the formula: MAP=(systolic BP+2 
x diastolic BP)/3. 
Statistical Analysis 
Analyses were conducted using SPSS. Missing cases (due to equipment malfunction or other 
data collection problems) were deleted list wise, which led to smaller sample sizes for some 
analyses. For subjective measures collected at multiple time points, peak or peak change from 
baseline was calculated for the purpose of analysis and concise representation in data tables. 
Subjective effects of the drug were assessed using repeated measures analysis of variance 
(ANOVA), with dose as a within-subjects factors. MDMA vs. placebo and MA vs. placebo were 
analyzed separately, with linear contrasts used for the MDMA analysis, given the two doses. 
Subjective and psychophysiological data from the touch tasks were analyzed with repeated 
measures ANOVAs, with dose and touch velocity as within-subject factors. The ABT was also 
analyzed with repeated measures ANOVAs, with dose as a within-subjects factor. Significant 
main effects and interactions were followed with post hoc t-tests corrected for multiple 
comparisons with the Benjamini-Hochberg procedure with a false discovery rate of 0.05.  
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Table 1: Participant demographics. Demographic and drug use characteristics reported as N 
(%) or M (SD) 
 
Sex  
   Male 18(50) 
   Female 18(50) 
Race  
   Caucasian 22(61) 
   African American 5(14) 
   Asian 5(14) 
   Other 4(11) 
Age 24.8(4.2) 
BMI 23.3(1.1) 
Education in years 15.2(1.5) 
Substance use  
Alcoholic drinks/week 3.7(2.3) 
MDMA (number of times used) 11.1 (9.8) 
 
 
Results 
Demographics 
The subjects were men and women with a mean age of 24.8 (± 4.2), most of whom were 
Caucasian (61%) with some post-graduate education. They reported an average reported MDMA 
use of 11.1 ± 9.8 times in their lifetime. Demographic characteristics are summarized in Table 1.  
Subjective Drug Effects 
Both doses of MDMA and the single dose of MA increased participants’ reports of “feel 
drug,” [MDMA F(1,35)=144.53, p<0.001; both doses vs. placebo p<0.001; MA F(1,35)=18.2, 
p<0.001; Supplementary Table 1] “like drug,” [MDMA F(1,35)=68.55, p<0.001; both doses vs. 
placebo p<0.001; MA F(1,35)=25.0, p<0.001], and “feel high,” [MDMA F(1,35)=109.22, 
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p<0.001; 0.75mg/kg vs. placebo p<0.01, 1.5mg/kg vs. placebo p<0.001; MA F(1,35)=17.5, 
p<0.001]. The higher dose of MDMA increased ratings of “dislike drug,” [MDMA F(1,35)=13.4, 
p<0.01; 1.5mg vs. placebo p<0.01] and all doses increased ratings of “want more” [MDMA 
F(1,35)=13.4, p<0.001; 0.75mg/kg vs. placebo p<0.01 and 1.5mg vs. placebo p<0.001; MA 
F(1,35)=27.5, p<0.001].  
The higher dose of MDMA increased ratings of “anxious” [MDMA F(1,35)=6.78, 
p<0.05; 1.5mg/kg vs. placebo p<0.05]. Both the higher dose of MDMA and MA increased 
ratings of “insightful” [MDMA F(1,35)=6.78, p<0.05; 1.5mg/kg vs. placebo p<0.05; MA 
F(1,35)=11.86, p<0.01] and “stimulated [MDMA F(1,35)=10.25, p<0.01; 1.5mg/kg vs. placebo 
p<0.01; MA F(1,35)=5.22, p<0.05]. MA significantly increased ratings of “sociable,” [MA 
F(1,35)=6.40, p<0.05] and “lonely” [MA F(1,35)=8.42, p<0.01]. MA increased ratings of 
“playful,” and 1.5mg/kg MDMA tended to do the same [MDMA F(1,35)=5.8, p<0.05; 1.5mg/kg 
vs. placebo p=0.06; MA F(1,35)=4.6, p<0.05]. MA increased ratings of “loving” [MA 
F(1,35)=5.58, p<0.05]. All doses increased ratings of “restless” [MDMA F(1,35)=15.01, p<0.01; 
0.75mg/kg vs. placebo p<0.01 and 1.5mg/kg vs. placebo p<0.01; MA F(1,35)=1.44, p<0.01]. 
None of the doses significantly affected ratings of confident, friendly, or dizzy (see 
Supplemental Table 1).  
Cardiovascular Drug Effects  
MA and both doses of MDMA significantly increased MAP and heart rate [MAP: MDMA F(2, 
70)=24.6, p<0.001; placebo vs. 0.75mg/kg MDMA, p<0.01; placebo vs. 1.5mg/kg MDMA 
p<0.001; MA F(1,35)=30.9, p<0.001; heart rate: MDMA F(2,70)=27.6, p<0.001; placebo vs. 
0.75mg/kg MDMA, p<0.01; placebo vs. 1.5mg/kg MDMA p<0.01; MA F(1,35)=25.7, p<0.001].  
Experienced Touch Task 
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Self-report: Ratings of pleasantness differed across the two velocities  [Figure 1A; F(1,35) = 
38.0, p < 0.001], such that CT-optimal (slow) touch was always rated as more pleasant than non-
optimal touch. Further, both doses of MDMA increased self-reported ratings of pleasantness 
[F(2,70) = 7.27, p < 0.05] for slow touch. Follow-up tests revealed that ratings of slow touch 
were marginally enhanced following the low dose of MDMA (p = 0.051) and significantly 
enhanced following the high dose of MDMA (p = 0.012). Analysis of the MA sessions revealed 
no significant main effect of the drug  (Supplementary Table 1). There was no significant effect 
of drug on ratings of non-optimal (fast) touch.  
Zygomatic: There was a linear dose effect of MDMA on zygomatic reactivity at both velocities 
[Figure 1B; F(1,33) = 8.04, p<0.01]. There was a trend towards a main effect of velocity [F(1,33) 
= 3.07, p = 0.09], but this did not reach significance. There was no significant effect of MA on 
zygomatic responses, or significant drug x velocity interaction (Supplementary Table 1).  
Corrugator: Consistent with prior findings, fast touch produced greater muscle activity than slow 
touch [Figure 1C; main effect of velocity; F(1,31) = 13.9, p < 0.01], but the drug/dose had no 
significant effect on this measure (F(1,32)=0.25 p = 0.66). Post hoc tests revealed that fast touch 
(30 cm/s) elicited greater corrugator activity than slow touch (CT-optimal; 3 cm/s) during the 
placebo session (p = 0.013) and high dose MDMA session (p = 0.007), but elicited no significant 
difference during the low dose MDMA or MA sessions. There was no significant effect of MA 
on corrugator reactivity (Supplementary Table 1).   
Observed Touch Task 
Self-report: Videos of slow touch were rated as more pleasant than fast and static touch, but there 
was no significant difference in ratings of static and fast touch [Supplementary Figure 1A; 
F(2,70) = 21.4, p < 0.001; 3cm/s vs. 0cm/s, p<0.001; 3cm/s vs. 30cm/s, p<0.001]. There was no 
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significant main effect of drug/dose or drug/dose x velocity interaction (Supplementary Table 1 
and 2).  
Zygomatic: There were no significant effects of velocity or drug on zygomatic reactivity 
(Supplementary Figure 1B and Supplementary Table 1), though there was a trend toward a linear 
effect of MDMA, as seen with the experienced touch task, such that MDMA increased 
zygomatic activity [F(1,30)=3.83, p=0.06]. 
Corrugator: There were no significant effects of velocity or drug on corrugator reactivity 
(Supplementary Figure 1C and Supplementary Table 1).  
Attention Bias Task 
At 1.5mg/kg, MDMA increased the total number of times participants looked toward happy 
faces before neutral faces (i.e., orienting attention), but did not affect gazes toward other emotion 
types [Figure 2; F(1,29)=4.45, p<0.05; placebo vs. 1.5mg/kg MDMA p<0.05; MA F(1,29)=0.32, 
p=0.58]. MA significantly increased first gazes toward angry faces [F(1,29)=5.1, p<0.05], but 
MDMA did not [F(1,29)=1.50, p=0.23]. Otherwise neither MDMA nor MA significantly 
affected initial gazes toward fear and sadness [MDMA F(1,29)=0.38, p=0.54; MA F(1,29)=0.15, 
p=0.7; MDMA F(1,29)=0.25, p=0.62; MA F(1,29)=0.09, p=0.77].  
Drug Identifications 
During the placebo session, 23 participants (63.9%) correctly guessed what they had received. 
The others guessed they had taken valium (22.2%), MDMA (5.6%), MA (5.6%), or marijuana 
(2.8%). During the MA session, 9 participants (25%) correctly guessed what they had received. 
The rest guessed they had taken valium (5.6%), MDMA (38.9%), marijuana (11.1%), or placebo 
(19.4%). During the 0.75mg/kg MDMA session, 17 participants (47.2%) correctly guessed what 
they had received. The rest guessed they had taken valium (25%), MA (5.6%), marijuana (8.3%), 
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or placebo (13.9%). During the 1.5mg/kg MDMA session, 25 participants (69.4%) correctly 
guessed what they had received. The rest guessed they had taken valium (11.1%), MA (16.7%), 
or placebo (2.8%). To assess the effects of expectancy on responses to affective touch, we 
compared pleasantness ratings for subjects who believed they had received MDMA after 
ingesting MA to those who believed they had received anything else, and ratings were not 
significantly different [t(34)=1.41, p=0.17]. 
Discussion 
In this study, we investigated the effects of MDMA and the prototypic stimulant MA, 
compared to placebo, on responses to two psychophysiological processes that may mediate the 
unique prosocial effects of MDMA: a novel measure of affective touch and visual attention to 
emotional faces. In accordance with our hypothesis, MDMA dose-dependently increased 
pleasantness ratings of affective touch at the CT-optimal frequency, without significantly 
affecting pleasantness of non-optimal touch. MA did not have this effect. Further and in line with 
these results, MDMA tended to increase pleasantness ratings for observed touch, although these 
effects were not significant. MDMA tended to increase zygomatic reactivity to touch at both 
frequencies, but did not significantly affect corrugator activity. MDMA also enhanced attention 
bias toward happy faces, but not significantly to other emotions, whereas MA did not have this 
effect. Taken together these findings advance our understanding of how MDMA influences 
social interaction.  
We examined affective responses to soft touch, using both subjective ratings and 
psychophysical indices (zygomatic and corrugator muscle activity).  Touch is a relatively recent 
and promising measure of social affective response. CT-optimal touch refers to physical touch 
that is between 1 and 10cm/s applied to hairy skin, and can be contrasted to non-optimal touch, 
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which is occurs outside this narrow frequency range, is rated as less pleasant than CT-optimal 
touch (Löken et al, 2009), and induces corrugator activation (Mayo et al, 2018). Further, in 
another study, participants were asked to stroke other individuals with whom they have intimate 
relationships (partners and babies) at any velocity, and reliably chose CT-optimal velocities, 
which they do not do when asked to stroke a wooden arm (Croy et al, 2016). CT-optimal touch 
preferentially activates the dorsal posterior insula (as compared to non-optimal touch), a region 
involved in affective tactile processing (Morrison, 2016). Interestingly this region is also 
implicated in increased resting state connectivity induced by MDMA (Bjornsdotter et al. 2017). 
This suggests that MDMA may act directly upon the neural circuits involved in responding to 
affective touch, which may explain subjective reports of increased touch pleasantness. Our 
results that MDMA enhances pleasantness ratings of affective touch are consistent with this 
evidence. 
In our study, MDMA increased zygomatic reactivity to both velocities of touch. This 
finding was unexpected, and may have been related to bruxism, a common side effect of MDMA 
(Winocur et al, 2003).  Although the facial EMG electrodes were placed to target the zygomatic 
muscle, there may have been some contamination from the masseter muscle, which could 
explain the relatively nonspecific increase in zygomatic activation to both velocities of touch at 
the higher dose of MDMA. In our study, for the high dose MDMA session, zygomatic responses 
during slow touch were correlated with pleasantness ratings (r=0.54, p<0.01), suggesting an 
alternative explanation of our results (beyond bruxism), that MDMA enhances positive 
psychophysiological responses to both CT-optimal and non-optimal touch. 
The mechanisms by which MDMA alters responses to affective touch are unknown. It 
has been has been suggested that MDMA produces prosocial effects by altering serotonergic 
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(Morley et al, 2005; Preller et al, 2016) and oxytocinergic signaling (Thompson et al, 2007). 
Changes in serotonergic signaling have been linked to changes in social behavior, and MDMA 
may lead to such changes (Bilderbeck et al, 2011; Bilderbeck et al, 2013). Several studies have 
reported that MDMA increases plasma oxytocin (Dumont et al, 2009; Hysek et al, 2012a; 
Kirkpatrick et al, 2014a; Wolff et al, 2006), even to levels that exceed those attained by the 
administration of intranasal oxytocin itself (Kirkpatrick et al. 2014).  Some studies (Dumont et 
al, 2009), but not others (Kuypers et al, 2014) find that plasma oxytocin levels are correlated 
with the prosocial effects of MDMA. A handful of studies have investigated the effects of 
intranasal oxytocin on the pleasantness of affective touch, but the findings have been 
inconclusive (Ellingsen et al, 2014; Scheele et al, 2014), and there is controversy about the 
amount of oxytocin that reaches the brain after intranasal administration (Leng and Ludwig, 
2016). MDMA has been shown to increase plasma oxytocin significantly more than the 
administration of intranasal oxytocin itself (Kirkpatrick et al, 2014a). Notably, MA, which did 
not increase ratings of pleasantness in this study, also does not increase plasma concentrations of 
oxytocin (Bershad et al 2015).   
The increase in oxytocin levels observed after the administration of MDMA may be 
secondary to the drug’s effects on the serotonergic system. Serotonin activates 5H-T1A receptors 
in the hypothalamus, which then leads to the release of oxytocin into the blood (Thompson et al, 
2007). Pharmacologic investigations into the role of the serotonergic system in producing the 
“empathogenic” effects of MDMA have provided some new evidence. While pretreatment with a 
selective serotonin reuptake inhibitor (SSRI) attenuates some subjective effects of MDMA, it is 
not clear if SSRIs specifically attenuate the social effects of MDMA (Liechti and Vollenweider, 
2001). Liechti et al. (2000) reported that the SSRI citalopram reduced effects of MDMA on 
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ratings of self-confidence and extraversion but it did not reduce ratings of emotional sensitivity 
and excitability.  Another study reported that the SSRI paroxetine dampened the effects of 
MDMA on both social and nonspecific measures of euphoria (i.e., “very happy,” and “more 
positive view about things”; Farré et al, 2007).  
Beyond the serotonergic system, noradrenergic and dopaminergic mechanisms may also 
contribute to some of the subjective effects of MDMA. Duloxetine, a serotonin-norepinephrine 
reuptake inhibitor, and reboxetine, a norepinephrine reuptake inhibitor, reportedly attenuate self-
reported prosocial effects of the drug (Hysek et al, 2011; Hysek et al, 2012b). MDMA can 
increase dopamine both directly and indirectly, and some of the positive mood effects of MDMA 
may be blocked by the administration of haloperidol (Liechti et al, 2001). In sum, serotonin, 
norepinephrine, and dopamine release likely contribute to some of the self-reported social effects 
of MDMA in humans, and the role of each neurotransmitter system in producing the effects 
observed in this study is a topic for further research. 
The finding that MDMA enhances the pleasantness of social touch has clinical 
implications for treatment of psychiatric disorders. MDMA has been used as an adjunct to 
psychotherapy in patients with PTSD (Mithoefer et al, 2011), and phase III clinical trials are 
underway to test its efficacy. Whether touch plays a role in this context remains to be 
determined. MDMA is also being considered in the treatment of Autism Spectrum Disorder 
(ASD). It has been shown to decrease social anxiety in autistic adults when used in combination 
with psychotherapy (Danforth et al, 2018; Danforth et al, 2016). Interestingly, a key symptom of 
ASD is altered touch processing (Cascio et al, 2008; Kaiser et al, 2015; Scheele et al, 2014): 
those with autistic traits find affective touch is less pleasant than healthy controls, and they 
exhibit reduced activity in brain regions sensitive to CT-optimal touch (Kaiser et al, 2015; Voos 
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et al, 2012). Thus, MDMA may act to boost responsiveness to CT-stimulation in these 
populations, and help to normalize affective responses to touch.    
The other finding in this study was that MDMA enhanced attention bias toward happy 
faces, as measured by eye movements. Previously, we showed that MDMA increased positive 
ratings of images with social content (Wardle et al, 2014b), and others showed that it increases 
some measures of emotional empathy (Dziobek et al, 2008; Hysek et al, 2014; Kuypers et al, 
2017). Other reports suggest that MDMA positively biases interpretation of emotional facial 
expressions, either by enhancing identification of positive expressions, interfering with 
identification of negative expressions, or both (Bedi et al, 2009; Hysek et al, 2012a; Kirkpatrick 
et al, 2014b; Wardle and de Wit, 2014a). Negative processing bias has been observed in multiple 
psychiatric disorders (Bishop, 2007; Rude et al, 2002), including PTSD (Litz et al, 2000), and 
the positive-biasing effects of MDMA we report here may underlie its effectiveness in a 
therapeutic context (Mithoefer et al, 2013; Mithoefer et al, 2011; Oehen et al, 2013; Wagner et 
al, 2017). 
Our study had a number of strengths. We studied two doses of MDMA, as well as 
placebo and the comparison drug MA, under double blind conditions.  The participants were 
carefully screened to limit variability in body weight, past and recent drug use history, 
psychiatric symptoms and in women, menstrual cycle phase. By administering the drug under 
double blind conditions, where subjects could expect to receive a stimulant (including MDMA), 
a tranquilizer, or a placebo, we minimized expectancies that can contribute to responses to drugs 
under non-laboratory conditions (Kirk et al, 1998; Mitchell et al, 1996). The use of two doses of 
MDMA helps to demonstrate the sensitivity of the tasks and the pharmacological profile of the 
drug. The use of a comparison drug, MA, helps to distinguish the effect of MDMA from that of a 
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prototypic psychostimulant. Finally, some of the measures used, including both subjective 
reports and psychophysiology, are standardized and sensitive indicators of psychoactive drug 
effects. The touch tasks were novel and open a new window of opportunities for 
psychopharmacology studies. 
A few limitations of this study warrant consideration. First, the participants were healthy 
adult volunteers with no psychiatric pathology, and it is not known if individuals with psychiatric 
symptoms would respond similarly to the drug. Second, we did not obtain measures of plasma 
oxytocin levels, which would have enabled us to speculate about a possible mechanism for the 
observed effects. Further, we focused in this study on affective touch applied to non-glabrous 
skin areas, which are innervated with CT-afferents. Follow-up studies could compare the effects 
of MDMA on responses to touch applied to both glabrous and non-glabrous skin. Finally, we 
tested the effects of MDMA in a highly controlled laboratory environment. For example, 
whereas the touch procedure used in this study was intended to simulate aspects of the real-world 
experience (e.g., social touch with a partner, family member, or other close friend), the procedure 
does not replace the actual experience of touch by these individuals. Both affective touch and the 
perception of emotional faces are likely more complex and more salient in real-world settings, 
and our study was unable to fully replicate these encounters.   
 In summary this is the first study to examine the effects of MDMA on responses to 
affective touch, and to directly compare those effects to another prototypical psychostimulant, 
MA. We showed that MDMA selectively enhances the pleasantness of CT-optimal touch, and 
that it biases visual attention to positive emotional faces. Both of these effects could contribute to 
the therapeutic efficacy of the drug. Interestingly, we compared MDMA to a psychostimulant 
drug without strong serotonergic effects (MA), and did not see similar effects on touch or 
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attention. Many questions remain, including questions of the precise mechanism by which these 
effects occur (e.g., via serotonergic, noradrenergic, dopaminergic, and oxytocinergic signaling), 
and whether the effects play a role in the therapeutic benefits of the drug in clinical populations. 
Further research will resolve these questions. 
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Figure Legends: 
Figure 1: Effects of MDMA, MA, and placebo on a) pleasantness ratings, b) zygomatic 
reactivity, and c) corrugator reactivity to CT-optimal and non-optimal experienced touch. 
* indicates a significant difference between drug and placebo, p<0.05. Statistical analysis was 
conducted on MDMA vs. placebo and MA vs. placebo separately, but doses are depicted 
together for the sake of clarity.  
Figure 2: Mean (± SEM) number of initial gazes toward emotional facial expressions after 
MDMA, MA, or placebo, shown for each emotion depicted. * indicates a significant 
difference between drug and placebo, p<0.05. 
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Supplementary Figure 1: Effects of MDMA, MA, and placebo on a) pleasantness ratings, b) 
zygomatic reactivity, and c) corrugator reactivity to CT-optimal and non-optimal observed 
touch. Statistical analysis was conducted on MDMA vs. placebo and MA vs. placebo separately, 
but doses are depicted together for the sake of clarity.  
 
 
 
 




Table 1: Participant demographics. Demographic and drug use characteristics reported as N 
(%) or M (SD) 
 
Sex  
   Male 18(50) 
   Female 18(50) 
Race  
   Caucasian 22(61) 
   African American 5(14) 
   Asian 5(14) 
   Other 4(11) 
Age 24.8(4.2) 
BMI 23.3(1.1) 
Education in years 15.2(1.5) 
Substance use  
Alcoholic drinks/week 3.7(2.3) 
MDMA (number of times used) 11.1 (9.8) 
  
